• Home
• About us
• Contact

• News
• People
• Products
• Deals
• Organisations

• Twitter
• Newsletter

Advertisement

Organisation › Details

Temedica GmbH

Temedica is a Munich, Germany-based digital health company with a mission to bring the patient into the center of healthcare. The company develops state-of-the-art digital patient companions for complex, chronic conditions. These apps support patients with personalized guidance and help them navigate through healthcare systems by considering their individual needs. Through direct and long-term interaction with patients, Temedica generates unique and previously unknown real-world evidence about disease progression and the individual effectiveness of therapies. Temedica has an expertise in the personalized support of patients as well as in compiling, structuring and analyzing respective health data. Its data analytics platform Permea is designed to enable unique insights along the entire healthcare value chain and patient journey. Temedica is supported by a consortium of renowned investors with longstanding track-records in the biopharmaceutical industry, including the founding investors of BioNTech. *

 

	Start	2017-12-06 renamed
	Predecessor	Physovia GmbH
	Industry	digital health (healthcare informatics)
	Industry 2	digital therapeutic (dTx)
	Person	Seibert, Gloria S. (Temedica 202001 Managing Director + Co-Founder)
	Person 2	Friedrich, Benjamin (Temedica 202201 CMO)
	Region	München (Munich)
	Country	Germany
	Street	27 Paul-Heyse-Str.
	City	80336 München
	Tel	+49-89-215544970
		Address record changed: 2020-12-02
Basic data	Employees	n. a.
		* Document for �About Section�: Temedica GmbH. (1/12/22). "Press Release: Temedica Introduces Permea. First Analytics Platform Integrating Patient-Generated Health Data". Munich.
		Record changed: 2022-03-16

Advertisement

More documents for Temedica GmbH

• [1] Temedica GmbH. (3/15/22). "Press Release: Temedica Announces Cooperation with Bristol Myers Squibb for the Development of a Digital Companion for Psoriasis Patients". Munich....

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Advertisement

» top

» Imprint  |  » Data Privacy  |  » Contact  |  The use of this website requires to accept the » Disclaimer!   |  A project of [iito] Business Intelligence © 2002-2022. Made in Germany.